Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

p38 MAPK and NF-κB Survival Pathways As Targets for Action of Rituximab In Vivo in a Xenographic Model,

Gabriel G Vega, PhD, Monica Arteaga-Campos, Bch, Melisa Martinez-Paniagua, PhD, Natividad Neri Munoz, PhD MD, M. J Nambo, Isabel Alvarado, Ivonne Cuadra, MD, Sara Huerta-Yepez, PhD, Mario Vega, PhD

Blood (2017) 130 (Supplement 1): 5199.

https://doi.org/10.1182/blood.V130.Suppl_1.5199.5199

Published: 2017

Journal Articles

Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL

Mario I Vega, PhD, Alejandro Aviles-Salas, MD, J Ramon Chalapud, MD, Sara Huerta-Yepez, PhD, Rogelio Hernandez-Pando, MD, PhD, Melisa Martinez-Paniagua, BSc, MSc, Bernardo Martinez-Miguel, BCh, Miriam Hernandez-Atenogenes, ChB, Gabriel G Vega, MDVZ, Haiming Chen, James R. Berenson, MD, Hector Mayani, PhD, Otoniel Martinez-Maza, PhD, Benjamin Bonavida, Ph.D

Blood (2011) 118 (21): 2647.

https://doi.org/10.1182/blood.V118.21.2647.2647

Published: 2011

Journal Articles

The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bcl xl ) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy

Melisa Martinez-Paniagua, BSc, MSc, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Hari Hariharan, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 2887.

https://doi.org/10.1182/blood.V116.21.2887.2887

Published: 2010

Journal Articles

An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Melisa Martinez-Paniagua, BSc, MSc, Stavroula Baritaki, PhD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 4919.

https://doi.org/10.1182/blood.V116.21.4919.4919

Published: 2010

Journal Articles

Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab

Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Melisa Martinez-Paniagua, BSc, MSc, Stavroula Baritaki, PhD, Haiming Chen, MD, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2010) 116 (21): 4931.

https://doi.org/10.1182/blood.V116.21.4931.4931

Published: 2010

Journal Articles

Upregulation of Krüppel-Like Factor 4 (KLF-4) Expression as a Potential Tumor Progression Gene Product in Non-Hodgkin's Lymphoma.

Mario I. Vega, PhD, Juan vazquez-Islas, Melisa Martinez-Paniagua, Miriam Hernandez-Atenogenes, Bernardo martinez-Miguel, Altagracia Maldonado-Valenzuela, B.Sc., Cesar Gonzalez-Bonilla, Sara Huerta-Yepez, PhD., Otoniel Martinez-Maza, Ph.D., Benjamin Bonavida, PhD

Blood (2009) 114 (22): 5022.

https://doi.org/10.1182/blood.V114.22.5022.5022

Published: 2009

Journal Articles

Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization

Mario I Vega, Ph.D., Melisa Martinez-Paniagua, Sara Huerta-Yepez, PhD., Benjamin Bonavida, PhD

Blood (2008) 112 (11): 2613.

https://doi.org/10.1182/blood.V112.11.2613.2613

Published: 2008

Journal Articles

Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF-Kb Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance

Melisa Martinez-Paniagua, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD., Stavroula Baritaki, James R. Berenson, MD, Haris Hariharan, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 3623.

https://doi.org/10.1182/blood.V112.11.3623.3623

Published: 2008

Journal Articles

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mario I. Vega, PhD, Melisa Martinez- Paniagua, Sara Huerta-Yepez, PhD., Eriko Suzuki, Kazuo Umezawa, Kam Yeung, Ph.D., Massimo Libra, Stavroula Baritaki, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4973.

https://doi.org/10.1182/blood.V112.11.4973.4973

Published: 2008

Journal Articles

Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1)

Melisa Martinez- Paniagua, Mario I. Vega, PhD, Sara Huerta-Yepez, PhD, Bonilla Gonzalez, PhD, Vanessa Suarez, Stavroula Baritaki, PhD, James R. Berenson, MD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4976.

https://doi.org/10.1182/blood.V112.11.4976.4976

Published: 2008

Journal Articles

Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1.

Mario I. Vega, PhD, Melisa Martinez-Paniagua, Sara Huerta-Yepez, PhD., Yeung Kam, Stavroula Baritaki, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 1596.

https://doi.org/10.1182/blood.V112.11.1596.1596

Published: 2008

Journal Articles

Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance

Stavroula Baritaki, PhD, Jose Rodriguez, Gustavo Helguera, PhD, Melisa Martinez-Paniagua, Mario Vega, PhD, Sara Huerta-Yepez, PhD., Ali Jazirehi, PhD, Demetrios Spandidos, PhD, Manuel L Penichet, M.D., Ph.D., Benjamin Bonavida, PhD

Blood (2008) 112 (11): 3770.

https://doi.org/10.1182/blood.V112.11.3770.3770

Published: 2008

NARROW

p38 MAPK and NF-κB Survival Pathways As Targets for Action of Rituximab In Vivo in a Xenographic Model,

Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL

The Pivotal Role of Yin Yang 1 (YY1) Inhibition (and downstream Bcl-2/Bcl xl ) by Galiximab (anti-CD80 mAb) In the Reversal of Resistance of B-NHL Cells to Chemotherapy

An ADCC-Independent Mechanism of Rituximab-Mediated B-NHL Cells Depletion Via Sensitization to Cell Death through the Expression of TRAIL on NK Cells

Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab

Upregulation of Krüppel-Like Factor 4 (KLF-4) Expression as a Potential Tumor Progression Gene Product in Non-Hodgkin's Lymphoma.

Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization

Galiximab (anti-CD80 mAb)-Induced Cell Triggering Results in the Inhibition of Constitutive NF-Kb Activity in Raji: Contrasting Roles of Snail and RKIP in the Regulation of Drug/Immune Resistance

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mechanism of Obatoclax (GX15-070; Bcl-2 Family Inhibitor)-Induced-Sensitization of B-NHL Cells to TRAIL-Mediated Apoptosis: Inhibition of the NF-κB Survival Pathway and the DR5 Transcription Repressor Yin Yang1 (YY1)

Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1.

Identification of Differentially Expressed Genes in the Rituximab- Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only